Survival And Pleurodesis Response Markers In Malignant Pleural Effusion-The Promise Study

management strategies. Additionally our results identify four biological pathways with the potential to guide novel treatments of MPE. developed using clinical data from three existing patient cohorts combined with biochemical measurements of pleural fluid and has not been prospectively assessed. This study reports the development and validation of the survival and pleurodesis response markers in MPE (PROMISE), the first score dedicated to the prospective assessment of the survival of patients with MPE simultaneously employing clinical, biological, and radiological parameters. Data and samples from patients recruited to previously published multinational, multicentre clinical trials with identical and established recruitment criteria were used.

[1]  N. Rahman,et al.  Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial , 2017, BMJ Open Respiratory Research.

[2]  Lu Shi,et al.  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.

[3]  J. M. Porcel,et al.  Malignant pleural effusion: from bench to bedside , 2016, European Respiratory Review.

[4]  Anoop Chauhan,et al.  Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. , 2015, JAMA.

[5]  N. Maskell,et al.  Individualised management of malignant pleural effusion. , 2015, The Lancet. Respiratory medicine.

[6]  G. Collins,et al.  Effect of Ebola Progression in Liberia , 2015, Annals of Internal Medicine.

[7]  R. Fischer,et al.  Gel-aided sample preparation (GASP)—A simplified method for gel-assisted proteomic sample generation from protein extracts and intact cells , 2015, Proteomics.

[8]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[9]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[10]  Brennan C Kahan,et al.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score , 2014, Thorax.

[11]  Huan Xia,et al.  Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis , 2014, PloS one.

[12]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[13]  H. Davies,et al.  Management of malignant pleural effusions: questions that need answers , 2013, Current opinion in pulmonary medicine.

[14]  C. Roussos,et al.  Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion , 2013, Oncogene.

[15]  Sun-Hee Kim,et al.  Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression , 2012, BMB reports.

[16]  H. Pass,et al.  Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. , 2012, The New England journal of medicine.

[17]  R. Davies,et al.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. , 2012, JAMA.

[18]  B. Nordestgaard,et al.  Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer , 2011, Critical reviews in clinical laboratory sciences.

[19]  B. Davidson,et al.  Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions , 2010, Clinical & Experimental Metastasis.

[20]  D Goldberg,et al.  Critical Reviews in Clinical Laboratory Sciences , 2010, Critical reviews in clinical laboratory sciences.

[21]  Chuanshu Huang,et al.  Inflammation, a Key Event in Cancer Development , 2006, Molecular Cancer Research.

[22]  Ralph B D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions. , 2005, Statistics in medicine.

[23]  C. Luparello,et al.  Tissue inhibitor of metalloprotease (TIMP)‐1 and proliferative behaviour of clonal breast cancer cells , 1999, Breast Cancer Research and Treatment.

[24]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[25]  HighWire Press.  European respiratory review : an official journal of the European Respiratory Society. , 1991 .

[26]  M. Tattersall,et al.  Management of malignant pleural effusions. , 1990, Thorax.